LncRNA RP11-259P1.1在小细胞肺癌组织中的表达及其临床意义  

Expression and clinical significance of lncRNA RP11-259P1.1 in small cell lung cancer tissues

作　　者：李晓华[1] 代斌 周婷[2] 周菁[2] 肖贞良[2] LI Xiaohua;DAI Bin;ZHOU Ting;ZHOU Jing;XIAO Zhenliang(Department of Respiratory,the Sixth People＇s Hospital of Chengdu,Chengdu 610051,Sichuan,China;Department of Respiratory,General Hospital of Chengdu Military Region,Chengdu 610083,Sichuan,China)

机构地区：[1]成都市第六人民医院呼吸内科,四川成都610051 [2]成都军区总医院呼吸内科,四川成都610083

出　　处：《中国肿瘤生物治疗杂志》2018年第10期1042-1047,共6页Chinese Journal of Cancer Biotherapy

基　　金：国家自然科学基金资助项目(NO.81700081)~~

摘　　要：目的:探讨长链非编码RNA RP11-259P1.1(lncRNA RP11-259P1.1)在小细胞肺癌(small cell lung cancer,SCLC)患者组织中的表达与患者临床病理特征的关系及其在化疗耐药中的作用。方法:收集2012年1月至2016年12月在成都市第六人民医院和成都军区总医院158例行支气管镜活检、穿刺活检和手术切除的SCLC患者的癌组织、42例SCLC患者手术切除的癌旁组织标本及40例正常肺组织,采用qPCR法检测癌及癌旁组织标本中lncRNA RP11-259P1.1的表达,χ2检验分析lncRNA RP11-259P1.1表达与SCLC患者临床病理特征及化疗耐药的关系。单因素及多因素Cox回归分析lncRNA RP11-259P1.1表达与SCLC患者预后的关系。结果:lncRNA RP11-259P1.1在SCLC组织中的表达水平显著高于癌旁组织及正常肺组织(均P<0.01)。化疗敏感者癌组织中lncRNA RP11-259P1.1的表达水平明显低于化疗耐药者(P<0.05)。lncRNA RP11-259P1.1表达与SCLC患者的性别、年龄无关,与肿瘤分期、转移及化疗敏感性显著相关(均P<0.05);高表达lncRNA RP11-259P1.1患者的PFS及OS均显著短于低表达患者[(12.25±1.83)vs(22.29±1.58)个月和(23.55±1.35)vs(31.75±2.43)个月,均P<0.01]。lncRNA RP11-259P1.1表达、肿瘤分期及远处转移是SCLC患者独立的预后因素(均P<0.05)。结论:lncRNA RP11-259P1.1在SCLC组织中高表达,与SCLC患者的化疗敏感性及预后相关,可能是SCLC患者潜在的预后评估的生物标志物。Objective： To explore the expression of long non-coding RNA RP11-259P1.1 （lncRNA RP11-259P1.1） in small cell lung cancer （SCLC） tissues and to analyze the relationship between lncRNA RP11-259P1.1 expression and SCLC clinicopathological characteristics,as well as to investigate its effect in chemoresistance. Methods： Tissue samples, including 158 cases of tumor tissues from SCLC patients, who underwent bronchoscopic biopsy, puncture biopsy and surgical resection, 48 cases of para-cancerous tissues and 40 cases of normal lung tissues, collected from January 2012 to December 2016 in the Sixth People’s Hospital of Chengdu and General Hospital of Chengdu Military Region,were used in this study. The expression of lncRNA RP11-259P1.1 was detected by Real-time fluorescence quantitative PCR （qPCR）. χ2 test was used to analyze the relationship between the expression of lncRNA RP11-259P1.1 and the clinicopathological characteristics as well as chemotherapeutic resistance in SCLC patients. Relationship between lncRNA RP11-259P1.1 expression and prognosis of SCLC patients was analyzed by univariate and multivariate Cox regression analysis. Results： The expression of lncRNA RP11-259P1.1 in SCLC tissues was significantly higher than that in para-cancerous tissues and normal lung tissues （all P 〈 0.01）. The expression of lncRNA RP11-259P1.1 in cancer tissues of chemosensitive group was significantly lower than that of chemoresistant group （P〈0.05）. The expression of lncRNA RP11-259P 1.1 was not correlated with gender and age, but significantly correlated with tumor stage, metastasis and chemosensitivity （all P〈0.05）. PFS and OS in patients with high lncRNA RP11-259P 1.1 expression were significantly shorter than those in patients with low expression （[12.25±1.83] vs [22.29±1.58] months, [23.55±1.35]vs [31.75±2.43] months, all P〈0.01）. The expression of lncRNA RP11-259P 1.1, tumor stage and distant metastasis were the independent prognostic factors in SCLC patients （all P〈0.05�

关 键 词：小细胞肺癌 长链非编码RNA RP11-259P1.1 化疗耐药 预后 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]